Single cell RNA sequencing of melanoma tumour dissociates treated ex vivo with MAPK inhibitors

BRAFV600-mutant melanoma tissue dissociates derived from tumor biopsies of treatment-naive melanoma patients (n=5) and patients who had progressed on immune checkpoint inhibitors (n=5) were treated ex vivo with combination BRAF/MEK inhibitors dabrafenib and trametinib or control (DMSO) before single-cell RNA sequencing (sc-RNAseq) to dissect the molecular features of response in distinct melanoma cell states.